Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.4.1 (phosphodiesterase)
 18,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study was made in the urological clinic of I.M. Sechenov Moscow Medical Academy with participation of 96 patients (mean age 48.24 +/- 9.19 years) with erectile dysfunction (ED) associated with hypogonadism. The patients were divided into three groups. Group 1 (n = 30) received 1 intramuscular injection of testosterone undecanoate. Group 2 (n = 34) received on-demand monotherapy with vardenafil for 6 weeks. Group 3 (n = 32) received combined treatment with the above modalities in the same doses and duration. Before and 6 weeks after treatment the patients responded to IIEF-5 questionnaire. All the patients showed a significant improvement of the erectile function. Overall AMS score after the treatment rose more in patients of groups 1 and 3 (p < 0.001). In group 2 the changes were weaker but significant (p = 0.005). The domain of psychological AMS symptoms reduced insignificantly after treatment in group 2 (p = 0.535), but significantly in groups 1 and 3, respectively (p = 0.013 vs p = 0.001). Androgenic deficiency regressed in groups 1 and 3 but enhanced in group 2 (p = 0.001). Domain of sexual symptoms of the AMS scale reduced more significantly in patients of groups 2 and 3 (p < 0.001). Percentage of patients satisfied with the treatment results was 68.85, 70,6 and 90,6% in groups 1, 2 and 3, respectively. Thus, combined treatment of erectile dysfunction in patients with hypogonadism (parenteral testosterone undecanoate and vardenafil) is more effective than monotherapy with androgen-containing drugs or inhibitors of phosphodiesterase of type 5.
 ...
PMID:[Choice of treatment of erectile dysfunction associated with hypogonadism]. 2096 81

The article presents the results of treatment of 155 patients with BPH aged 48-65 years, who received conservative treatment for this disease. The patients were divided into three groups. Group 1 consisted of patients with BPH and erectile dysfunction (ED), who underwent conservative treatment (5alpha-reductase inhibitors in combination with alpha1-adrenoblocker) and phosphodiesterase inhibitor (tadalafil 20 mg) on demand. Group 2 consisted of patients with prostatic adenoma and ED, who received only conservative therapy. Group 3 consisted of BPH patients without ED, who received only conservative therapy. The effectiveness of treatment was assessed using patient self-assessment questionnaire. I-PSS score was used for the assessment of symptoms of the disease, for assessment of sexual function--AMS questionnaire for the age-related symptoms in men (specific section), short BSFI questionnaire, and International Index of Erectile Function (IIEF-5). Questionnaire survey was performed before treatment and 3, 6 and 9 months after therapy. Analysis of the results showed that there were significant impairments of sexual function in BPH. The use of phosphodiesterase inhibitor against the background of conservative therapy improves erectile function, and reduces the intensity of urination disorders.
 ...
PMID:[Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy]. 2378 65